title: Outcome of valve repair and the Cox maze procedure for mitral regurgitation and associated atrial fibrillation.
abstract: OBJECTIVE
  The objective was to determine whether the Cox maze procedure provides adjunctive benefit in patients with atrial fibrillation undergoing mitral valve repair.
  
  
  METHODS
  We compared the outcome of 39 patients who had the Cox maze procedure plus mitral valve repair between January 1993 and December 1996 (maze group) with that of 58 patients with preoperative atrial fibrillation who had mitral valve repair during the same interval by the same surgeons (control group). Patients in the 2 cohorts were similar for age, gender, preoperative New York Heart Association class III or IV, and duration of preoperative atrial fibrillation. The control group had a higher incidence of previous heart surgery and coronary artery disease.
  
  
  RESULTS
  No operative deaths occurred, and 1 patient in each group required pacemaker implantation after the operation. Duration of cardiopulmonary bypass (122 +/- 40 minutes vs 58 +/- 27 minutes, P <.0001) and hospitalization (12.6 +/- 6.4 vs 9.3 +/- 3.4 days, P <.0025) were prolonged in patients having the Cox maze procedure. Overall, 2-year survival was similar (92% +/- 5% for maze patients and 96% +/- 3% for controls). Freedom from atrial fibrillation in the maze group was 74% +/- 8% 2 years after the operation compared with 27% +/- 7% for the control group (P <.0001). Freedom from stroke or anticoagulant-associated bleeding in the maze group was 100% 2 years after the operation compared with 90% +/- 8% in the control group (P =.04). At most recent follow-up, 82% of maze patients were in normal sinus rhythm (53% in control group).
  
  
  CONCLUSIONS
  The addition of the Cox maze procedure to mitral valve repair is safe and effective for selected patients, and elimination of atrial fibrillation decreased late complications.
authors.affiliation: Division of Thoracic Surgery, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA.
authors.forename: N
authors.initials: N
authors.lastname: Handa
authors.forename: H V
authors.initials: HV
authors.lastname: Schaff
authors.forename: J J
authors.initials: JJ
authors.lastname: Morris
authors.forename: B J
authors.initials: BJ
authors.lastname: Anderson
authors.forename: S L
authors.initials: SL
authors.lastname: Kopecky
authors.forename: M
authors.initials: M
authors.lastname: Enriquez-Sarano
mesh_terms: D000368:Aged; D000925:Anticoagulants / Q000009:adverse effects; D001281:Atrial Fibrillation / Q000601:surgery*; D006348:Cardiac Surgical Procedures; D002315:Cardiopulmonary Bypass; D015331:Cohort Studies; D003327:Coronary Disease / Q000150:complications; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006339:Heart Rate / Q000502:physiology; D006470:Hemorrhage / Q000139:chemically induced; D006760:Hospitalization; D006801:Humans; D015994:Incidence; D007902:Length of Stay; D008297:Male; D008943:Mitral Valve / Q000601:surgery*; D008944:Mitral Valve Insufficiency / Q000601:surgery*; D010138:Pacemaker, Artificial; D018579:Patient Selection; D012449:Safety; D020521:Stroke / Q000209:etiology; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000925:Anticoagulants